Parkinson's Disease Clinical Trial
Official title:
The Study of Acupuncture on Vascular and Functional Neuroimaging in Parkinson's Disease Patients With Sleep Disorders
Verified date | April 2021 |
Source | Tsinghua University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to compare vascular and functional neurological changes of acupuncture in patients with Parkinson's Disease and Sleep Disorders. In the randomized controlled clinical trial study, patients meeting the criteria for inclusion will be randomly enrolled and divided into two groups in a 1:1 ratio: the acupuncture group and the sham acupuncture group. The intervention is going to be executed using the acupoints GV14(Dazhui)and GB20 (Fengchi).The acupuncture needles will be inserted to a depth of 0.8 to 1 cm using GV14(Dazhui)and GB20 (Fengchi) in the acupuncture group. The sham acupuncture group's needles will be inserted to a depth of 0.1 to 0.2 cm with nonacupuncture points located 0.5 cm in lateral to the real acupoint or to the right for midline points.During the study, researchers will observe changes in cerebral blood vessels and neuroimaging before and after acupuncture in the two groups. Using multimodal fusion advanced vascular-neuronal imaging techniques could evaluate the effect of acupuncture on brain blood vessels and function in patients with Parkinson's disease and Sleep Disorders and provide an objective neuroimaging basis for assessing the effectiveness of acupuncture.
Status | Completed |
Enrollment | 15 |
Est. completion date | September 30, 2020 |
Est. primary completion date | June 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. meeting the above diagnostic criteria for Parkinson's disease and Sleep Disorders; 2. Hoehn-Yahr grade 2-3; 3. Those who voluntarily participate in the project while he/she or his/her guardian sign an informed consent form; 4. Those who have had a junior high school education or above and have a correct understanding of clinical acupuncture research significance. Exclusion Criteria: 1. Accompanied with sleep apnea syndrome, sleep-behavioral disorders such as sleep-breathing disorders, and other system diseases that cause sleep disorders, such as anemia and other hematological diseases, hypothyroidism, severe heart and lung diseases, tumors, liver and kidney diseases; 2. History of drug use or alcohol addiction, psychosis and sedation for painful illnesses; 3. Severe cognitive impairments and failure to complete scale assessments; 4. There are barriers to communication and communication that affect the evaluation of research, such as speech, vision, hearing and other serious damage to patients; 5. Allergic to needles or alcohol; 6. Those who cannot perform MRI scans, such as claustrophobia. |
Country | Name | City | State |
---|---|---|---|
China | Tsinghua University Yuquan Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Tsinghua University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cerebral blood flow data change | Neuroimaging assessment by 3D SNAP-MRA | Through once acupuncture completion, 30 minutes | |
Secondary | Parkinson's Disease Sleep Scale | Scale evaluation.Scale Range:0-150.Higher values represent a better outcome. | Through once acupuncture completion, 30 minutes | |
Secondary | Pittsburgh Sleep Quality Index | Scale evaluation.Scale Range:0-21.Higher values represent a worse outcome. | Through once acupuncture completion, 30 minutes | |
Secondary | Epworth Sleepiness Scale | Scale evaluation.Scale Range:0-24.Higher values represent a worse outcome. | Through once acupuncture completion, 30 minutes | |
Secondary | Unified Parkinson's Disease Rating Scale | Scale evaluation.Scale Range:0-149.Higher values represent a worse outcome. | Through once acupuncture completion, 30 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |